The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine – A phase I randomized clinical trial
Background: Development of an efficacious egg-free mock-up H5N1 vaccine is key to our preparedness against pandemic avian flu. Methods: This is a single-center, randomized, observer-blinded phase I clinical trial evaluating the safety and immunogenicity of an alum-adjuvanted Madin–Darby canine kidne...
Published in: | Journal of Microbiology, Immunology and Infection |
---|---|
Main Authors: | , , , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Elsevier
2019
|
Subjects: | |
Online Access: | https://doi.org/10.1016/j.jmii.2019.03.009 https://doaj.org/article/b0907daaec2e4aae84ad5f05d69fb80a |
id |
ftdoajarticles:oai:doaj.org/article:b0907daaec2e4aae84ad5f05d69fb80a |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:b0907daaec2e4aae84ad5f05d69fb80a 2023-05-15T15:34:31+02:00 The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine – A phase I randomized clinical trial Aristine Cheng Szu-Min Hsieh Sung-Ching Pan Yu-Han Li Erh-Fang Hsieh Hsiang-Chi Lee Ting-Wan Lin Kuan-Lang Lai Charles Chen Stanley Shi-Chung Chang Shan-Chwen Chang 2019-10-01T00:00:00Z https://doi.org/10.1016/j.jmii.2019.03.009 https://doaj.org/article/b0907daaec2e4aae84ad5f05d69fb80a EN eng Elsevier http://www.sciencedirect.com/science/article/pii/S1684118218301762 https://doaj.org/toc/1684-1182 1684-1182 doi:10.1016/j.jmii.2019.03.009 https://doaj.org/article/b0907daaec2e4aae84ad5f05d69fb80a Journal of Microbiology, Immunology and Infection, Vol 52, Iss 5, Pp 685-692 (2019) Microbiology QR1-502 article 2019 ftdoajarticles https://doi.org/10.1016/j.jmii.2019.03.009 2022-12-31T13:23:33Z Background: Development of an efficacious egg-free mock-up H5N1 vaccine is key to our preparedness against pandemic avian flu. Methods: This is a single-center, randomized, observer-blinded phase I clinical trial evaluating the safety and immunogenicity of an alum-adjuvanted Madin–Darby canine kidney (MDCK)-derived inactivated whole-virion H5N1 influenza vaccine in healthy adults. Hemagglutination inhibition (HAI) and neutralizing antibody titers were measured using horse and turkey red blood cells (RBCs). Results: Thirty-six adult subjects were randomized to receive two doses of 0.5 mL of the MDCK-derived H5N1 alum-adjuvanted vaccine containing 7.5, 15, or 30 μg of hemagglutinin (HA) 21 days apart. The candidate vaccine was well tolerated and safe across the three dosing groups. The most frequent adverse event was injection site pain (46.5%). Both HAI and neutralizing antibody titers increased after each vaccination in all three dosing groups. The best HAI responses, namely a seroconversion rate of 91.7% and a geometric mean ratio of 9.51 were achieved with the HA dose of 30 μg assayed using horse RBCs at day 42. HAI titers against H5N1 avian influenza virus was significantly higher when measured using horse RBCs compared with turkey RBCs. Conclusions: This Phase I trial showed the MDCK-derived H5N1 candidate vaccine is safe and immunogenic. The source of RBCs has a significant impact on the measurement of HAI titers (ClinicalTrials.gov number: NCT01675284.). Keywords: Influenza A, Avian influenza, H5N1, Vaccination, Immune response Article in Journal/Newspaper Avian flu Directory of Open Access Journals: DOAJ Articles Darby ENVELOPE(162.217,162.217,-77.667,-77.667) Journal of Microbiology, Immunology and Infection 52 5 685 692 |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
English |
topic |
Microbiology QR1-502 |
spellingShingle |
Microbiology QR1-502 Aristine Cheng Szu-Min Hsieh Sung-Ching Pan Yu-Han Li Erh-Fang Hsieh Hsiang-Chi Lee Ting-Wan Lin Kuan-Lang Lai Charles Chen Stanley Shi-Chung Chang Shan-Chwen Chang The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine – A phase I randomized clinical trial |
topic_facet |
Microbiology QR1-502 |
description |
Background: Development of an efficacious egg-free mock-up H5N1 vaccine is key to our preparedness against pandemic avian flu. Methods: This is a single-center, randomized, observer-blinded phase I clinical trial evaluating the safety and immunogenicity of an alum-adjuvanted Madin–Darby canine kidney (MDCK)-derived inactivated whole-virion H5N1 influenza vaccine in healthy adults. Hemagglutination inhibition (HAI) and neutralizing antibody titers were measured using horse and turkey red blood cells (RBCs). Results: Thirty-six adult subjects were randomized to receive two doses of 0.5 mL of the MDCK-derived H5N1 alum-adjuvanted vaccine containing 7.5, 15, or 30 μg of hemagglutinin (HA) 21 days apart. The candidate vaccine was well tolerated and safe across the three dosing groups. The most frequent adverse event was injection site pain (46.5%). Both HAI and neutralizing antibody titers increased after each vaccination in all three dosing groups. The best HAI responses, namely a seroconversion rate of 91.7% and a geometric mean ratio of 9.51 were achieved with the HA dose of 30 μg assayed using horse RBCs at day 42. HAI titers against H5N1 avian influenza virus was significantly higher when measured using horse RBCs compared with turkey RBCs. Conclusions: This Phase I trial showed the MDCK-derived H5N1 candidate vaccine is safe and immunogenic. The source of RBCs has a significant impact on the measurement of HAI titers (ClinicalTrials.gov number: NCT01675284.). Keywords: Influenza A, Avian influenza, H5N1, Vaccination, Immune response |
format |
Article in Journal/Newspaper |
author |
Aristine Cheng Szu-Min Hsieh Sung-Ching Pan Yu-Han Li Erh-Fang Hsieh Hsiang-Chi Lee Ting-Wan Lin Kuan-Lang Lai Charles Chen Stanley Shi-Chung Chang Shan-Chwen Chang |
author_facet |
Aristine Cheng Szu-Min Hsieh Sung-Ching Pan Yu-Han Li Erh-Fang Hsieh Hsiang-Chi Lee Ting-Wan Lin Kuan-Lang Lai Charles Chen Stanley Shi-Chung Chang Shan-Chwen Chang |
author_sort |
Aristine Cheng |
title |
The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine – A phase I randomized clinical trial |
title_short |
The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine – A phase I randomized clinical trial |
title_full |
The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine – A phase I randomized clinical trial |
title_fullStr |
The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine – A phase I randomized clinical trial |
title_full_unstemmed |
The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine – A phase I randomized clinical trial |
title_sort |
safety and immunogenicity of a cell-derived adjuvanted h5n1 vaccine – a phase i randomized clinical trial |
publisher |
Elsevier |
publishDate |
2019 |
url |
https://doi.org/10.1016/j.jmii.2019.03.009 https://doaj.org/article/b0907daaec2e4aae84ad5f05d69fb80a |
long_lat |
ENVELOPE(162.217,162.217,-77.667,-77.667) |
geographic |
Darby |
geographic_facet |
Darby |
genre |
Avian flu |
genre_facet |
Avian flu |
op_source |
Journal of Microbiology, Immunology and Infection, Vol 52, Iss 5, Pp 685-692 (2019) |
op_relation |
http://www.sciencedirect.com/science/article/pii/S1684118218301762 https://doaj.org/toc/1684-1182 1684-1182 doi:10.1016/j.jmii.2019.03.009 https://doaj.org/article/b0907daaec2e4aae84ad5f05d69fb80a |
op_doi |
https://doi.org/10.1016/j.jmii.2019.03.009 |
container_title |
Journal of Microbiology, Immunology and Infection |
container_volume |
52 |
container_issue |
5 |
container_start_page |
685 |
op_container_end_page |
692 |
_version_ |
1766364878429224960 |